Amprenavir approved
- PMID: 11366753
Amprenavir approved
Abstract
AIDS: The FDA has approved amprenavir (Agenerase), the fifth protease inhibitor (PI) to be approved and the first PI approved in 2 years. When used in triple combination therapy, amprenavir is effective in viral suppression in treatment-naive patients and some patients who have taken NRTIs and NNRTIs. The drug has also been shown to be effective in about half of the patients who are resistant to other PIs. The standard dose for amprenavir is eight large capsules taken twice a day. Levels of amprenavir may be affected by the concurrent use with efavirenz (Sustiva). Common side effects of amprenavir include nausea, vomiting, diarrhea, and numbness and tingling around the mouth.
Similar articles
-
Amprenavir, new protease inhibitor, approved.AIDS Treat News. 1999 May 7;(No 318):1-3. AIDS Treat News. 1999. PMID: 11366454
-
Drug approval.AIDS Policy Law. 1999 Apr 30;14(8):12. AIDS Policy Law. 1999. PMID: 11366532
-
Coming therapies: amprenavir.Int J Clin Pract Suppl. 1999 Jun;103:42-4. Int J Clin Pract Suppl. 1999. PMID: 10622044 Review.
-
Amprenavir (Agenerase) receives FDA approval. Food and Drug Administration.BETA. 1999 Apr;12(2):3. BETA. 1999. PMID: 11366693
-
Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor.Clin Ther. 2000 May;22(5):549-72. doi: 10.1016/S0149-2918(00)80044-2. Clin Ther. 2000. PMID: 10868554 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous